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Other names: DKFZP434N0250; PKBG; PRKBG; 
RAC-PK-gamma 
Location: 1q44 




The AKT3 gene is composed of 14 exons spanning a 
genomic region of 354,937 bp. 
Transcription 
AKT3 coding sequence consists of 1,440 bp from the 
start codon to the stop codon. 
Protein 
Description 
The AKT3 serine/threonine kinase consists of 479 
amino acids with a calculated molecular weight of 55.8 
kDa (approximate molecular weight of 59-60 kDa seen 
on a Western blot). The protein contains three 
important regions: the PH domain at the N terminus 
(residues 1-107), a kinase domain (residues 148-405), 
and a C-terminal regulatory domain (residues 406-479). 
A 465-amino acid splice variant lacking the serine 472 
residue has been identified, which results from 
alternative splicing of an exon at the C terminus. 
Expression 
Northern blot analysis of AKT3 indicated that it is 
expressed in virtually all tissues, predominantly in the 
brain and fetal heart and at lower levels in liver and 
skeletal muscle. RT-PCR analysis also indicated 
expression of AKT3 in a wide variety of tissues. 
Localisation 
Predominantly cytoplasmic; also found at the plasma 
membrane and in the nucleus following its activation. 
Function 
AKT family members are serine/threonine kinases 
activated following stimulation by growth factors, 
hormones and the extracellular matrix. AKT kinases 
play a key role in proliferation, cell survival, and 
tumorigenesis. Binding of ligands (e.g., EGF) to 
tyrosine kinase receptors or G-protein coupled 
receptors leads to the recruitment and activation of the 
Class 1A and Class 1B PI3K (Phosphatidylinositol 3-
Kinase), respectively. The pleckstrin homology domain 
of AKT kinases has affinity for the 3'-phosphorylated 
phosphoinositides 3,4,5-trisphosphate (PI-3,4,5-P3) and 
PI-3,4-P2 produced by PI3K, and they are activated 
specifically by the latter lipid. Phospholipid bindg 
triggers the translocation of AKT kinases to the plasma 
membrane. There, AKT is activated through 
phosphorylation of a threonine (T308 in AKT1, T309 
in AKT2 and T305 in AKT3) by PDK1 and on a serine 
(S473 on AKT1, S474 on AKT2, and S472 on AKT3) 
by PDK2. Activated AKT then phosphorylates a 
number of different substrates involved in survival, cell 
cycle progression, and other pathways implicated in 
tumorigenesis. 
Homology 
AKT3 is a serine/threonine kinase and is a member of 
the AKT family that also includes AKT1 and AKT2. At 
the protein level, AKT3 shows overall 83.6% identity 
with AKT1 and 78% identity with AKT2. The three 
AKT kinases are identical in the ATP binding region, 
except for one residue: Ala 230 of AKT1 is conserved 
in AKT2 (Ala 232), but switches to Val 228 in AKT3. 
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Diagram of the AKT3 protein in scale. The numbers represent specific residues. The domains are PH (Pleckstrin Homology), a short 
helical region, Kinase (Catalytic Kinase), and Regulatory (Regulatory Region). Indicated are the two phosphorylation sites shown to be 
essential for activation of AKT3: Threonine 305 and serine 472. C: Carboxyl-terminal; N: Amino-terminal. 
Mutations 
Note: No germline or somatic mutations were 




AKT3 was found to be expressed at a higher level in 
estrogen receptor-negative breast cancer compared to 
estrogen receptor-positive cancers, thus possibly 
contributing to the more aggressive phenotype of the 
former. AKT3 activity was also 30-to 60-fold higher in 
two estrogen receptor-negative cell lines as compared 
to two estrogen receptor-positive cell lines. 
Hepatocellular carcinoma (Hepatitis C 
virus related) 
Oncogenesis 
Using array-CGH analysis, gene copy number 
increases of AKT3 were found in 6 out of 19 (32%) 
tumors, including small, well-differentiated 
carcinomas. Thus, increased copies of the gene may 
play a potentially important role in the onset of 
Hepatitis C-related hepatocellular carcinoma. 
Melanoma 
Oncogenesis 
AKT3 was demonstrated to be the predominant AKT 
isoform involved in melanoma tumorigenesis. 
Knockdown of AKT3 with siRNA was shown to 
decrease total phospho-AKT levels in four melanoma 
cell lines and in normal melanocytes. In contrast, 
targeting the other two AKT proteins had no effect. 
AKT3 protein was overexpressed in 60% of primary 
melanoma tumors compared to normal melanocytes. 
Immunoprecipitation of AKT3 followed by 
immunoblotting with a phospho-specific AKT antibody 
indicated that 43% of primary melanomas have 
increased AKT3 activity compared to normal controls. 
Moreover, siRNA-mediated knockdown of AKT3 in a 
melanoma cell line led to a dramatic decrease in 
xenograft tumor size as a result of increased apoptosis. 
Ovarian cancer 
Oncogenesis 
AKT3 was discovered to be highly expressed in 19 out 
of 92 (20%) primary ovarian tumors and also expressed 
in a number of ovarian tumor cell lines, including two 
cell lines having duplications of the AKT3 gene. The 
high expression of AKT3 in cell lines appeared to 
correlate with high total phospho-AKT levels, 
increased proliferation, and the ability to grow in serum 
starved conditions. SiRNA-mediated silencing of 
AKT3 expression in the OVCA429 and DOV13 cell 
lines resulted in reduced proliferation due to inhibition 
of the cell cycle. 
Prostate cancer 
Oncogenesis 
AKT3 was found to be expressed at a higher level and 
with a 20- to 40-fold higher activity in androgen-
insensitive prostate cancer compared to androgen-
sensitive prostate cancer. The loss of PTEN expression 
appeared to contribute to increased AKT3 activity in 
one of the cell lines examined. Thus, AKT3 may play a 
role in the more aggressive phenotype of androgen-
insensitive prostate cancers. 
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